Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A1 | Q14973 | 18/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22906130 | 0.94 | SLC10A1 (0.49) | SLC10A1GRM4LRRK2 | |
| SCHEMBL25645185 | 0.90 | SLC10A1 (0.47) | SLC10A1GRM4LRRK2 | |
| SCHEMBL31659293 | 0.84 | SLC10A1 (0.49) | SLC10A1GRM4LRRK2 | |
| SCHEMBL21427896 | 0.84 | SLC10A1 (0.49) | SLC10A1GRM4LRRK2 | |
| SCHEMBL30361236 | 0.84 | SLC10A1 (0.49) | SLC10A1GRM4LRRK2 | |
| SCHEMBL21408544 | 0.84 | SLC10A1 (0.49) | SLC10A1GRM4LRRK2 | |
| SCHEMBL21408543 | 0.84 | SLC10A1 (0.49) | SLC10A1GRM4LRRK2 | |
| SCHEMBL25645190 | 0.84 | SLC10A1 (0.46) | SLC10A1GRM4LRRK2 | |
| SCHEMBL22545726 | 0.84 | SLC10A1 (0.51) | SLC10A1GRM4 | |
| SCHEMBL30361242 | 0.82 | SLC10A1 (0.47) | SLC10A1GRM4LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183208-A1 | N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183208-A1 | N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | COG5, HAVCR2, ZC3HAV1 | SLC10A1 35/4885GRM4 4715/4885LRRK2 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.